FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206190711> ?p ?o ?g. }

• W3206190711 abstract "Abstract Background The most well-known cause of cancer deaths identified in female is breast cancer. Several drugs approved by the food and drug administration (FDA) for the treatment of breast cancer may have adverse health effects. This research is aimed at developing a QSAR model and utilize it to predict the inhibitive activities of newly designed novel compounds, examine their ADMET and drug-likeness properties and carry out molecular docking studies between the designed compounds and the VEGFR-2 receptors in order to identify the essential amino acid residues involved in protein–ligand interactions and possible mechanism of action of the designed compounds. Results The first model was selected as the best because of its fitness statistically with the following assessment parameters: R 2 train = 0.832, R 2 adj = 0.79, R 2 ext = 0.62, Q 2 = 0.68, and LOF = 0.14509. Compound 11 was selected as a template to design new powerful compounds based on its low residual and high pIC 50 values. Majority of the designed compounds has predicted pIC 50 greater than that of the lead compound and the standard drug (Sunitinib) used as reference. Molecular docking studies results of the designed compounds revealed that they have higher docking scores than the template and the reference drug (Sunitinib) and are found to bind to the VEGFR-2 receptor in a similar manner to the reference drug. Pharmacokinetics and ADMET properties revealed that the designed compounds passed drug-likeness criteria because they did not violate more than 1 Lipinski’s rule of Five, They are uniformly distributed to the brain and are assumed to penetrate the central nervous system and finally they are all found to non-toxic and orally bioavailable. Conclusion The developed model was therefore found to be efficient in predicting the pIC 50 of Anti breast cancer compounds that are yet to be synthesized and it also help in reducing the cost and synthetic duration the compounds. The result of this research confirmed that the designed compounds may be developed as novel VEGFR-2 inhibitors." @default.
• W3206190711 created "2021-10-25" @default.
• W3206190711 creator A5017427535 @default.
• W3206190711 creator A5030647920 @default.
• W3206190711 creator A5046028790 @default.
• W3206190711 creator A5083963903 @default.
• W3206190711 date "2021-10-09" @default.
• W3206190711 modified "2023-10-16" @default.
• W3206190711 title "Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents" @default.
• W3206190711 cites W1917948530 @default.
• W3206190711 cites W2011588810 @default.
• W3206190711 cites W2016522688 @default.
• W3206190711 cites W2017422910 @default.
• W3206190711 cites W2041242595 @default.
• W3206190711 cites W2056017994 @default.
• W3206190711 cites W2076018148 @default.
• W3206190711 cites W2087661061 @default.
• W3206190711 cites W2093449680 @default.
• W3206190711 cites W2097006862 @default.
• W3206190711 cites W2116581459 @default.
• W3206190711 cites W2156614826 @default.
• W3206190711 cites W2157120864 @default.
• W3206190711 cites W2166573361 @default.
• W3206190711 cites W2179406551 @default.
• W3206190711 cites W2550696748 @default.
• W3206190711 cites W2593436234 @default.
• W3206190711 cites W2776121059 @default.
• W3206190711 cites W2785262536 @default.
• W3206190711 cites W2789119707 @default.
• W3206190711 cites W2789530016 @default.
• W3206190711 cites W2903600395 @default.
• W3206190711 cites W2907064064 @default.
• W3206190711 cites W2973230479 @default.
• W3206190711 cites W3000157125 @default.
• W3206190711 doi "https://doi.org/10.1186/s42269-021-00631-w" @default.
• W3206190711 hasPublicationYear "2021" @default.
• W3206190711 type Work @default.
• W3206190711 sameAs 3206190711 @default.
• W3206190711 citedByCount "13" @default.
• W3206190711 countsByYear W32061907112022 @default.
• W3206190711 countsByYear W32061907112023 @default.
• W3206190711 crossrefType "journal-article" @default.
• W3206190711 hasAuthorship W3206190711A5017427535 @default.
• W3206190711 hasAuthorship W3206190711A5030647920 @default.
• W3206190711 hasAuthorship W3206190711A5046028790 @default.
• W3206190711 hasAuthorship W3206190711A5083963903 @default.
• W3206190711 hasBestOaLocation W32061907111 @default.
• W3206190711 hasConcept C104317684 @default.
• W3206190711 hasConcept C112705442 @default.
• W3206190711 hasConcept C121608353 @default.
• W3206190711 hasConcept C126322002 @default.
• W3206190711 hasConcept C159110408 @default.
• W3206190711 hasConcept C164126121 @default.
• W3206190711 hasConcept C185592680 @default.
• W3206190711 hasConcept C21951064 @default.
• W3206190711 hasConcept C2775905019 @default.
• W3206190711 hasConcept C2779490328 @default.
• W3206190711 hasConcept C2780035454 @default.
• W3206190711 hasConcept C3018146709 @default.
• W3206190711 hasConcept C41685203 @default.
• W3206190711 hasConcept C41847442 @default.
• W3206190711 hasConcept C55493867 @default.
• W3206190711 hasConcept C70721500 @default.
• W3206190711 hasConcept C71240020 @default.
• W3206190711 hasConcept C71924100 @default.
• W3206190711 hasConcept C86803240 @default.
• W3206190711 hasConcept C98274493 @default.
• W3206190711 hasConceptScore W3206190711C104317684 @default.
• W3206190711 hasConceptScore W3206190711C112705442 @default.
• W3206190711 hasConceptScore W3206190711C121608353 @default.
• W3206190711 hasConceptScore W3206190711C126322002 @default.
• W3206190711 hasConceptScore W3206190711C159110408 @default.
• W3206190711 hasConceptScore W3206190711C164126121 @default.
• W3206190711 hasConceptScore W3206190711C185592680 @default.
• W3206190711 hasConceptScore W3206190711C21951064 @default.
• W3206190711 hasConceptScore W3206190711C2775905019 @default.
• W3206190711 hasConceptScore W3206190711C2779490328 @default.
• W3206190711 hasConceptScore W3206190711C2780035454 @default.
• W3206190711 hasConceptScore W3206190711C3018146709 @default.
• W3206190711 hasConceptScore W3206190711C41685203 @default.
• W3206190711 hasConceptScore W3206190711C41847442 @default.
• W3206190711 hasConceptScore W3206190711C55493867 @default.
• W3206190711 hasConceptScore W3206190711C70721500 @default.
• W3206190711 hasConceptScore W3206190711C71240020 @default.
• W3206190711 hasConceptScore W3206190711C71924100 @default.
• W3206190711 hasConceptScore W3206190711C86803240 @default.
• W3206190711 hasConceptScore W3206190711C98274493 @default.
• W3206190711 hasIssue "1" @default.
• W3206190711 hasLocation W32061907111 @default.
• W3206190711 hasOpenAccess W3206190711 @default.
• W3206190711 hasPrimaryLocation W32061907111 @default.
• W3206190711 hasRelatedWork W2033342433 @default.
• W3206190711 hasRelatedWork W2064956914 @default.
• W3206190711 hasRelatedWork W2090099591 @default.
• W3206190711 hasRelatedWork W2182709359 @default.
• W3206190711 hasRelatedWork W2764174910 @default.
• W3206190711 hasRelatedWork W2888207074 @default.
• W3206190711 hasRelatedWork W2989876214 @default.
• W3206190711 hasRelatedWork W3087336774 @default.
• W3206190711 hasRelatedWork W3152127249 @default.

• next